Viferon rectal 500tys.me 10 pc

$8.98

Viferon rectal 500tys.me 10 pc

Out of stock

Description

Composition
Active substance:
1 suppository viferon 150,000 IU contains the active substance: interferon alpha-2b human recombinant 150,000 IU 1 suppository viferon 500,000 IU contains the active substance: interferon alpha-2b human recombinant 500,000 IU 1 suppository viferon 1,000,000 IU contains the active substance: interferon alfa-2b, recombinant human 1,000,000 IU, 1 suppository viferon 3 000 000 IU contains the active substance: interferon alpha-2b, recombinant human 3 000 000 IU ,.
Excipients:
Viferon 1 suppository contains 150 000 IU: ascorbic acid 0.0054 g, 0.0108 g of sodium ascorbate, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g Polysorbate 80 0.0001 g of cocoa butter 0.1958 g, confectionary fat or cocoa butter substitute to 1 g viferon 1 suppository contains 500 000 IU: ascorbic acid 0.0081 g, 0.0162 g of sodium ascorbate, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g polysorbate 80 0.0001 g, 0.1941 g of cocoa butter, vegetable fat, or cocoa butter substitute to 1 g suppository 1 viferon 1,000,000 IU comprising: ascorbic acid 0.0081 g, 0.0162 g of sodium ascorbate, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g Polysorbate 80 0.0001 g, 0.1941 g of cocoa butter, vegetable fat or cocoa butter substitute to 1 g 1 suppository viferon 3 000 000 IU comprising: ascorbic acid 0.0081 g, 0.0162 g of sodium ascorbate, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g polysorbate 80 0.0001 g of cocoa butter 0 1941, confectionery fat or cocoa butter substitute to 1 g
Description:
Valium Valium forms, white with a yellowish tinge, homogeneous consistency. Heterogeneity of coloring in the form of marbling. On the longitudinal section has a funnel-shaped recess. Suppository diameter not exceeding 10 mm.
Product form:
Cuppozitorii rectal 150,000 IU 500 000 IU, 1,000,000 IU 3,000,000 IU.
5 or 10 suppositories in blisters PVC / PVC. 1 blisters 10 suppositories or 2 blisters 5 suppository with instructions for use in a stack of cardboard.
Contraindications
Hypersensitivity to any component of the drug.
Dosage
500 thousand. IU
Indications
Acute respiratory viral infections, including influenza, including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of combination therapy; infectious and inflammatory diseases of newborns, including premature: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus, enterovirus infection, candidiasis, including visceral, mycoplasmosis) in the complex therapy; chronic viral hepatitis B, C, D in children and adults in a complex therapy, including in combination with plasmapheresis and hemosorption chronic viral hepatitis pronounced activity complicated cirrhosis; infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, bacterial vaginosis, HPV infection, bacterial vaginosis, recurrent vaginal candidiasis, a mycoplasmosis) in adults as part of combination therapy; primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild to moderate over, including urogenital form in adults.
Interaction with other drugs
Viferon, rectal suppositories, and compatible blends well with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy drugs, steroids).
Overdose
Not installed.
pharmachologic effect
Pharmacological group:
Cytokine.
Pharmacological properties:
Interferon alfa-2b, recombinant human possesses antiviral, immunomodulatory, antiproliferative properties, inhibits the replication of RNA and DNA containing viruses. Immunomodulating properties of interferon alpha-2b such as enhancement of the phagocytic activity of macrophages, increase specific cytotoxicity of lymphocytes for target cells, mediated determine its antibacterial activity.
In the presence of ascorbic acid and alpha-tocopherol acetate increased the specific antiviral activity of interferon alpha-2b, amplifies its immunomodulatory effects, which allows to increase the effectiveness of its own immune response to pathogenic microorganisms. In applying the drug increased levels of secretory immunoglobulin A, normalized IgE levels, there is a restoration operation of the endogenous alpha-2b interferon system. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants have anti-inflammatory, membrane stabilizing and regenerating properties. It found that by applying the drug viferon no side effects arising when parenterally administered preparations of interferon alpha-2b, do not produce antibodies that neutralize the antiviral activity of interferon alpha-2b. Application viferon drug in combined therapy can reduce the therapeutic doses of antibiotics and hormonal drugs, but also reduce the toxic effects of said therapy.
Cocoa butter contains phospholipids which allow not used in the production of synthetic emulsifiers are toxic, and the presence of polyunsaturated fatty acids facilitates the introduction and dissolution of the drug.
Pregnancy and breast-feeding
The drug is approved for use with the 14 th week of pregnancy. Not particularly limited to the application during breastfeeding.
Conditions of supply of pharmacies
Available without a prescription.
side effects
In rare cases, allergic reactions (skin rashes, itching). These phenomena are reversible and disappear within 72 hours after discontinuation.
Storage conditions
Store at 2 to 8 C, protected from light.
Keep out of the reach of children.
Dosing and Administration
The drug is used rectally. 1 suppository contains as active substance interferon alfa-2b, recombinant human in dosages indicated (150 000 IU 500 000 IU, 1,000,000 IU 3,000,000 IU).
Acute respiratory viral infections, including influenza, including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of combination therapy.
The recommended dose for adults, including pregnant women and children older than 7 years – viferon 500,000 IU 1 suppository 2 times a day, 12 hours daily for 5 days. For clinical therapy can be continued.
Under 7, including a premature newborn and gestational age of over 34 weeks, it is recommended to use the drug viferon 150,000 IU 1 suppository 2 times a day every 12 hours daily for 5 days. For clinical therapy can be continued. Interval between courses of 5 days.
Preterm neonates with gestational age less than 34 weeks of drug application is recommended viferon 150,000 IU 1 suppository 3 times a day at 8 hours daily for 5 days. For clinical therapy can be continued. Interval between courses of 5 days.
Infectious-inflammatory diseases of newborns, including premature: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus, enterovirus infection, candidiasis, including visceral, mycoplasmosis) in the complex therapy.
The recommended dosage for infants, including premature infants with gestational age of over 34 weeks – viferon 150,000 IU daily 1 suppository 2 times a day after 12 h treatment course -. 5 days.
Preterm neonates with gestational age less than 34 weeks of drug application is recommended viferon 150,000 IU daily 1 suppository 3 times a day at 8 hours course of treatment -. 5 days.
The recommended number of courses at different infectious and inflammatory diseases: sepsis – 2-3 course, meningitis – 1-2 course, herpes infection – 2 courses, enterovirus infection – 1-2 courses, cytomegalovirus infection – 2-3 courses, mycoplasmosis, candidiasis, including visceral – 2-3 courses. Interval between courses of 5 days. For clinical therapy can be continued.
Chronic viral hepatitis B, C, D in children and adults in a complex therapy, including in combination with plasmapheresis and hemosorption chronic viral hepatitis pronounced activity complicated cirrhosis.
The recommended dose for adults – viferon 3 000 000 IU 1 suppository 2 times a day every 12 hours daily for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
Children under the age of 6 months is recommended 300 000-500 000 IU per day; aged 6 to 12 months – 500 000 IU per day.
Children aged 1 to 7 years recommended 3 million IU per 1 m2 of body surface area per day.
Children older than 7 years recommended 5 million IU per 1 m2 of body surface area per day.
The drug is used 2 times a day every 12 hours the first 10 days of every day, then three times a week every other day for 6-12 months. The duration of treatment is determined by the clinical efficacy and laboratory parameters.
Calculation of a daily dosage for each patient is performed by multiplying the recommended dose for age on body surface area, calculated according to a nomogram for calculating the area of ​​the body surface height and weight of Garford, Rourke and Terry. Calculation of a single dose is performed by dividing the calculated daily dose administration at 2, the obtained value is rounded to a greater dosage suppository side.
In chronic viral hepatitis pronounced activity and cirrhosis prior to plasmapheresis and / or hemosorption recommended the use of children under the age of 7 years drug viferon 150,000 IU, children older than 7 years old – viferon 500,000 IU 1 suppository 2 times a day 12 hours daily for 14 days.
Infectious-inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, bacterial vaginosis, HPV infection, bacterial vaginosis, recurrent vaginal candidiasis, a mycoplasmosis) in adults, including pregnant women, in the complex therapy.
The recommended dose for adults – viferon 500,000 IU 1 suppository 2 times a day every 12 hours daily for 5-10 days. For clinical therapy can be continued.
Pregnant with II trimester of pregnancy (ranging from 14 weeks of gestation) recommended the use of the drug viferon 500,000 IU 1 suppository 2 times a day every 12 hours daily for 10 days, then for 9 days, 3 times at intervals of 3 days ( on the fourth day) 1 suppository 2 times a day every 12 hours. Further, every 4 weeks until delivery – viferon 150,000 IU 1 suppository 2 times a day every 12 hours daily for 5 days.
If necessary, shown before delivery (from 38 weeks of gestation) using the product viferon 500,000 IU 1 suppository 2 times a day every 12 hours daily for 10 days.
Primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild to moderate over, including urogenital form in adults, including pregnant women.
The recommended dose for adults – viferon 1,000,000 IU 1 suppository 2 times a day every 12 hours daily for 10 days and more with recurrent infection. For clinical therapy can be continued. It is recommended to start treatment immediately at the first signs of skin and mucous membrane lesions (itching, burning, redness). In the treatment of recurrent herpes, it is desirable to begin treatment in the prodromal or early manifestation signs of relapse.
Pregnant with II trimester of pregnancy (ranging from 14 weeks of gestation) recommended the use of the drug viferon 500,000 IU 1 suppository 2 times a day every 12 hours daily for 10 days, then for 9 days, 3 times at intervals of 3 days ( on the fourth day) 1 suppository 2 times a day every 12 hours. Further, every 4 weeks until delivery – viferon 150,000 IU 1 suppository 2 times a day every 12 hours daily for 5 days. If necessary, shown before delivery (from 38 weeks of gestation) using the product viferon 500,000 IU 1 suppository 2 times a day every 12 hours daily for 10 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Fearon

There are no reviews yet.

Add your review